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Squamous cell carcinoma of the vulva is a disease of signiﬁcant clinical importance, which arises in the presence or absence of
human papillomavirus. We used comparative genomic hybridisation to document non-random chromosomal gains and losses
within human papillomavirus positive and negative vulvar cancers. Gain of 3q was signiﬁcantly more common in human
papillomavirus-positive cancers compared to human papillomavirus-negative cancers. The smallest area of gain was 3q22–25,
a chromosome region which is frequently gained in other human papillomavirus-related cancers. Chromosome 8q was more
commonly gained in human papillomavirus-negative compared to human papillomavirus-positive cancers. 8q21 was the
smallest region of gain, which has been identiﬁed in other, non-human papillomavirus-related cancers. Chromosome arms 3p
and 11q were lost in both categories of vulvar cancer. This study has demonstrated chromosome locations important in the
development of vulvar squamous cell carcinoma. Additionally, taken together with previous studies of human papillomavirus-
positive cancers of other anogenital sites, the data indicate that one or more oncogenes important in the development and
progression of human papillomavirus-induced carcinomas are located on 3q. The different genetic changes seen in human
papillomavirus-positive and negative vulvar squamous cell carcinomas support the clinicopathological data indicating that these
are different cancer types.
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Vulvar cancers affect 1.6 per 100000 women in Victoria, Australia,
85% of which are squamous cell carcinomas (SCC) (Canstat,
1998). There are two clinicopathological types of SCC of the vulva:
those that contain human papillomavirus (HPV) DNA and those
that do not. HPV-positive vulvar SCCs share common epidemiolo-
gical features with SCC of the vagina, cervix and anal region. HPV
has been detected in less than 50% of vulvar SCCs (in Frierson and
Mills, 1999). These HPV-positive tumours occur in women on
average 14 years younger when compared to HPV-negative vulvar
cancers, tend to be basaloid in appearance and arise from classical
(Bowenoid) vulvar intraepithelial neoplasia (VIN) (Scurry et al,
1998). The pathogenesis of HPV-negative cancers is less well
understood, but these cancers frequently arise on a background
of lichen sclerosus, squamous cell hyperplasia and simplex (differ-
entiated) type of VIN. These different clinicopathological features
suggest that there may be different genetic changes in HPV-positive
and negative cancers.
The process of HPV-related carcinogenesis within SCC of the
anogenital region depends on functions encoded by the viral E6
and E7 genes. These genes bind with the p53 and Rb genes,
respectively, inactivating their function in cell cycle regulation
(Munger et al, 1989). However, many women have been exposed
to HPV without developing premalignant or malignant changes
within the vulva, and thus it is likely that additional genetic
changes are necessary for tumour development and progression.
Furthermore, other than a small number of studies addressing loss
of heterozygosity using a limited number of markers, few studies
have addressed whether HPV-positive vulvar cancers share similar
genetic changes to those seen in HPV-negative cancers, or whether
these two types of SCC of the vulva share separate molecular
pathogeneses (Flowers et al, 1999; Pinto et al, 1999; Scurry et
al, 1999).
Comparative genomic hybridization (CGH) is a powerful tool
in the study of cancer that has fast gained recognition for its abil-
ity to scan an entire genome for DNA copy number changes that
are mapped to chromosome regions. HPV-positive and negative
vulvar cancers were analysed using CGH in order to determine
speciﬁc chromosomal regions of DNA copy number gain and loss
and to compare these changes with the HPV status of the
tumours.
PATIENTS AND METHODS
The 18 patients with vulvar cancer used in this study were treated
surgically between 1982 and 1999 at The Mercy Hospital for
Women. Pathologic review was performed and the histologic type
conﬁrmed as SCC.
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CGH was carried out according to methods described in detail
elsewhere (Allen et al, 2000). Brieﬂy, areas of interest (2–
3m m
2) were microdissected from parafﬁn-embedded formalin-
ﬁxed tissue sections and digested with proteinase K. MCF7 cell-
line DNA and reference control DNAs from peripheral blood
lymphocytes were extracted using a Progenome kit (Progen,
Ipswich, Australia). DOP–PCR was performed on all reference
and tumour samples and MCF-7 control DNA as previously
described by Kuukasjarvi et al (1997). The CGH result using
DOP–PCR ampliﬁed MCF-7 control showed all the same changes
as an intra-laboratory MCF-7 standard CGH proﬁle using non-
ampliﬁed DNA. Ampliﬁed DNA samples were labelled by nick
translation using the Bionick labelling system (Life Technologies,
Gaithersburg, MD, USA). Both a primary and conﬁrmatory
CGH experiment was performed for each sample using different
labels to control for variation of different ﬂuorochromes. Firstly,
tumour samples were directly labelled with Spectrum Red and
hybridised with biotin labelled reference DNA. In the conﬁrma-
tory hybridisation tumour samples were labelled with
digoxigenin and hybridised with reference DNA directly labelled
with Spectrum Green. Only changes seen in both hybridisations
were used in the results. Following washing, biotinylated DNA
was detected by streptavidin-conjugated ﬂuorescein isothiocyanate
(FITC) (Vector Laboratories, Burlingame, CA, USA) and digoxi-
genin-labelled DNA by mouse anti-digoxigenin antibody
conjugated to rhodamine (TRITC) (Boehringer-Mannheim,
Germany). Samples were counterstained with 4,6-diamino-2-
phenylindole (DAPI). Each CGH experiment included at least
one normal lymph node DNA as a negative control. Images were
analysed with Quips CGH Analysis Software (Vysis Inc, Downers
Grove, IL, USA). A gain of DNA sequence copy number was
deﬁned by a tumour/reference ratio 41.2 on both standard and
inverse hybridisation. A copy number decrease was deﬁned as
having a tumour/reference ratio below 0.8 on both hybridisations.
No distinction was attempted between high-level copy number
increases (ampliﬁcations) of subregions as contrasted to gains of
a whole arm.
HPV methods
Determination of HPV status was carried out according to meth-
ods described in detail elsewhere (Allen et al, 2000). Brieﬂy 7 mm
sections of parafﬁn-embedded vulvar tumours were dewaxed, and
digested with proteinase. Samples were ampliﬁed for 40 cycles
using 50 rmol of each of the Ll consensus primers MY09 and
MY11 (Manos et al, 1989) and 5 rmol of each of the two beta-
globin primers GH20-PC04 (Resnick et al, 1990). DNA from
cloned HPV 6, 11, 16, 18, 31 and 33 was used as positive controls
and DNA extracted from normal placenta as negative controls.
Ampliﬁcation products were hybridised with biotin-labelled HPV
Ll generic probe (Bauer et al, 1991) and captured on streptavidin
coated plates (Roche Biochemicals) (Layton-Henry et al, 1996).
The bound hybrid was detected by an anti-digoxigenin peroxidase
conjugate by use of the colourimetic substrate ABTS (Layton-
Henry et al, 1996). The positive HPV specimens were typed for
HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52 with type-speciﬁc
probes (Resnick et al, 1990) using similar detection methods as
described above.
Statistical analysis
The Fisher’s exact test was used to compare proportions from two
independent samples, while the two-sample independent-groups t-
test was used to compare the difference between means. All tests
were two-sided and results with a P-value of less than 0.05 were
considered statistically signiﬁcant.
RESULTS
The HPV analysis showed that there were 8 HPV-negative tumours
and 10 HPV-positive tumours. All HPV-positive tumours
contained subtype 16. Figure 1 represents the overall gains and
losses in the 18 vulvar tumours, mapped to speciﬁc chromosome
locations. The mean number of overall changes seen in the 18
tumours was 3.2 per case (range 0–5). This comprised a mean
of 1.3 gains per case (range 0–3) and a mean of 1.9 losses per case
(range 0–5). There were more CGH changes in the HPV-positive
group, compared to the HPV-negative group (mean 3.6, vs 2.8,
respectively) but this did not reach statistical signiﬁcance. The
increased number of changes in the HPV-positive group was due
to an excess number of losses in these tumours (mean number
of losses 2.4, vs 1.4, respectively). HPV-positive and negative
cancers had a mean of 1.2 and 1.4 gains per case, respectively.
Table 1 shows the four most common CGH changes in the
vulvar cancers and Figure 2 shows a representative CGH proﬁle
on an individual case. Chromosomal locations 8q (8 out of 18,
44%) and 3q (5 out of 18, 28%) were most frequently affected
by genetic gain, whilst 11q (8 out of 18, 44%) and 3p (5 out
of 18, 28%) were most frequently lost. There was a statistically
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Figure 1 Chromosome gains and losses in vulvar SCCs. (A) HPV-posi-
tive cancers and (B) HPV-negative cancers. Bars on the left side of the idio-
grams indicate a loss and bars on the right side indicate a gain of genetic
material.
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analysed by HPV status, with 3q gain being more common in
HPV-positive cancers (5 out of 10 vs 0 out of 8, P50.025),
and 8q gain more common in HPV-negative cancers (6 out of
8 vs 2 out of 10, P50.025). There was no statistically signiﬁcant
difference by HPV status for 11q and 3p loss. Whilst many
tumours showed whole chromosome arm alteration, minimal
regions of gain and loss could be determined from some indivi-
dual tumours. Thus the smallest areas of copy number gain
were mapped to 3q22–25 and 8q21 and loss to 3p24, and
11q22-qter.
DISCUSSION
In this study we have performed CGH analysis of SCC of the vulva,
with known HPV status. To our knowledge, this is the ﬁrst report
of a CGH-based, genome-wide analysis of chromosomal gains and
losses on this cancer type analysed by HPV status. Vulvar cancer
differs from other SCCs of the anogenital region, since a substantial
proportion of vulvar cancers are HPV-negative. The different HPV
status of these cancers is reﬂected in their different clinicopatholo-
gical parameters. We have utilised CGH to identify chromosomal
loci important in vulvar oncogenesis in general, as well as those
which differ according to the HPV status.
Several regions of recurrent chromosomal abnormality were
identiﬁed in vulvar SCCs. Notably gain of chromosome 3q was a
frequent ﬁnding in HPV-positive SCCs (50%), but not detected
in any of our HPV-negative cases. These data support gain of 3q
as an important event in the oncogenesis of HPV-related SCCs
since, in a previous study, we have shown that a similar proportion
of stage 1b HPV-positive cervical SCCs harbour 3q gain (Allen et
al, 2000). Gain of 3q has also been detected by others in cervical
SCCs (Heselmeyer et al, 1996, 1997b; Dellas et al, 1999; Kirchoff
et al, 1999) and in HPV-positive SCC of the anus and its precursor
lesions (Heselmeyer et al, 1997a; Haga et al, 2001). Further, we
were able to map the smallest region of gain in vulvar SCCs to
3q22–25, whilst our previous series of cervical cancers showed
the smallest area of gain to be 3q24–26 (Allen et al, 2000). Only
one previous CGH analysis of vulvar carcinoma has been
published, which detected 3q gain as the most common region
of gain (40% of 10 cases) (Jee et al, 2001). However, these tumours
were not assessed for HPV status. Our data indicate that 3q gain is
important primarily in HPV-positive vulvar cancers. Taken
together, our present data and past ﬁndings on cervical SCC, as
well as previous data showing 3q gain in other HPV-related
anogenital SCCs, suggest that this region of the genome harbours
gene(s) synergistic with HPV in oncogenesis and which are impor-
tant in the progression of HPV-induced SCCs of the anogenital
region.
Loss of the chromosome arms 11q and 3p were also
frequently detected in our series of vulvar cancers. Chromosome
3p loss has been previously documented in vulvar SCCs by LOH
studies (Flowers et al, 1999; Pinto et al, 1999) and by CGH (Jee
et al, 2001). The previous LOH studies indicate that the loss of
3p markers was not related to HPV status, which is supported
by our own CGH data. Furthermore, two of the microsatellite
markers showing LOH which were used in the previous studies
were mapped to the region of 3p24, which was the smallest
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Table 1 Common CGH changes in vulvar tumours by HPV status
Total 8q gain (%) 3q gain (%) 3p loss (%) 11q loss (%)
HPV-negative 6/8 (75) 0/8 (0) 1/8 (12.5) 4/8 (50)
HPV-positive 2/10 (20) 5/10 (50) 4/10 (40) 4/10 (40)
Total tumours 8/18 (44) 5/18 (28) 5/18 (28) 8/18 (44)
n=7 n=8 n=7 n=5 n=8
n=7 n=5 n=7 n=5 n=7 n=8 n=8
n=6 n=6 n=7 n=8 n=8 n=7
n=7 n=8 n=8 n=8 n=8 n=0
12 3 45
6 7 8 9 10 11 12
13 14 15 16 17 18
19 20 21 22 X Y
Figure 2 An individual CGH ratio proﬁle of a representative case of HPV-negative vulvar cancer. Gains are represented to the right of the midline on the
ideogram and losses to the left.
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study. Loss of 3p is also frequently seen in cervical SCC, by
CGH and LOH analysis (Heselmeyer et al, 1996, 1997b; Larson
et al, 1997; Wistuba et al, 1997; Kersemaekers et al, 1998; Steen-
bergen et al, 1998; Dellas et al, 1999; Kirchoff et al, 1999; Allen
et al, 2000). Loss of 11q has been documented in cervical and
other malignancies not related to HPV infection, including
breast, colorectal and ovarian cancers and malignant melanoma
(Hampton et al, 1994; Kersemaekers et al, 1998; Allen et al,
2000). Loss of 11q was frequently documented in our series of
vulvar cancers and was not related to HPV status. The smallest
region of loss could be mapped to 11q22-qter. We have
previously mapped the smallest region of chromosome loss on
11q in cervical cancers as 11q22–24 (Allen et al, 2000) and
an identical region has been previously mapped by LOH studies
in cervical cancer (Hampton et al, 1994). These data indicate
that, in contrast to genes on 3q, those on 3p and 11q may be
related to development and progression of anogenital SCC inde-
pendent of HPV status.
Recurrent gain of 8q was also detected in our series of vulvar
cancers. Interestingly, this gain was much more frequent in
HPV-negative compared to HPV-positive cancers (75% vs 20%,
respectively). The smallest area of gain was 8q21, which is centro-
meric to the location of the proto-oncogene MYC. Gain of 8q,
including the 8q21 region, has been previously documented in
many different cancer types, the majority of which are not related
to HPV infection (Kallioniemi et al, 1994; Prat et al, 2001; Shiraishi
et al, 2001; van Dekken et al, 2001). The current and other studies
therefore support the notion that 8q houses important oncogene(s)
other than MYC. Although our data would suggest that 8q gain is
important in the development of HPV-negative vulvar cancer, the
number of cases in the present study are too small to clearly indi-
cate whether 8q gain is redundant in the development of HPV-
positive vulvar cancers, as is documented for mutations in the
p53 gene (Flowers et al, 1999; Brooks et al, 2000).
Only one previous study describing CGH analysis of vulvar
carcinomas has been published (Jee et al, 2001). However, the
HPV status of these cases was unreported. Whilst the majority of
changes detected in this previous series is similar to our own, Jee
et al (2001) found the commonest detectable change to be 4p loss
(5 out of 10 cases). 4p loss was only detected in one of our 18 cases
(an HPV-positive case). Interestingly, one previous study of regions
of genomic loss in vulvar cancer detected by LOH found only two
of 11 cases to show loss of the 4p marker D4S2366 (Pinto et al,
1999). It is possible therefore that the difference in detection of this
regional loss between our own study and that of Jee et al (2001) is
due to the different demographics of the two populations studied,
confounded by the small number of cases studied in each series
and the probable relatively low incidence of 4p loss in vulvar
cancers overall.
Our ﬁndings indicate that SCC of the vulva harbour several
chromosomal alterations in common with other SCCs of the
anogenital region. Additionally, there appear to be selected chro-
mosomal regions in which copy number abnormalities are related
to HPV status. Identiﬁcation of candidate genes in these areas of
recurrent chromosomal copy number abnormality would give
important insights into the development and progression of vulvar
and other anogenital cancers.
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